IGNITE II, or Implementing GeNomics In pracTiCe, is an NIH-funded network dedicated to supporting the implementation of genomics in healthcare.
The network is comprised of five research sites that help promote the mission of IGNITE II through support from a coordinating center, working groups, affiliate members, and an external scientific panel.
Coordinating Center
Indiana University
Mount Sinai
Duke University
University of Florida
Vanderbilt Clinical Group
Coordinating Center
Working Groups
Affiliate Members
External Scientific Panel
RESEARCH SITES
Coordinating Center
Housed within the Duke Center for Applied Genomics and Precision Medicine and the Duke Clinical Research Institute, the overarching goal of the Coordinating Center (CC) is to ensure the success of the IGNITE II Network in designing, implementing and completing its genomic medicine pragmatic clinical trial (PCT) agenda. The CC will do this by providing genomic medicine and clinical trials expertise and leadership as well as the infrastructure, processes, state-of-the-art technology and data science solutions. The CC will serve as a catalyst for collaboration, both within and externally to the IGNITE II Network with the goal of demonstrating the network’s value to a broader group of genomic medicine stakeholders in order to promote a more rapid uptake of genomic medicine in clinical practice.
The CC provides a wide range of supporting activities, including:
- Providing strategic organizational leadership to develop a novel, flexible and adaptable genomic PCT network;
- Implementing an administrative management structure for the network that enables seamless communication, information sharing and optimum network productivity;
- Ensuring optimal and adaptable PCT design, participant recruitment and data collection;
- Developing a comprehensive analysis framework for evaluating the implementation and clinical effectiveness of the genomic medicine interventions; and
- Communicating and disseminating knowledge beyond the network.
PRINCIPAL INVESTIGATORS:
Geoffrey Ginsburg, M.D., Ph.D. – Director of the Duke Center for Applied Genomics & Precision Medicine and the MEDx Initiative; Professor of Medicine, Pathology and Biomedical Engineering
Hrishikesh Chakraborty, DrPH – Associate Director of the Duke Clinical Research Institute; Co-Director of Biostatistics and Computational Biology Core, Center for AIDS Research (CFAR)
Indiana University Health
Indiana University Health is a nonprofit healthcare system located in Indiana. It is the largest and most comprehensive healthcare system in the state with 16 hospitals under its IU Health brand and almost 30,000 employees. A unique partnership with Indiana University School of Medicine, one of the nation’s leading medical schools, gives patients access to leading-edge medicine and treatment options that are available first, and often only, at IU Health. The IU Health system has a total capacity of 2,696 beds with annual admissions of over 115,000 and more than 2.8 million outpatient visits per year.
Eskenazi Health System, partnering with the Indiana University School of Medicine, serves as the public hospital division of the Health & Hospital Corporation of Marion County. Eskenazi Health provides a comprehensive range of primary and specialty care services at the 315-bed hospital and outpatient facilities both on and off the Eskenazi Health downtown campus as well as at 10 Eskenazi Health Center sites located throughout Indianapolis. Eskenazi Health’s programs have received national recognition while also offering new health care opportunities to the local community. As the sponsoring hospital for Indianapolis Emergency Medical Services, the city’s primary EMS provider, Eskenazi Health is also home to the first adult Level I trauma center in Indiana, the only verified adult burn center in Indiana, the first community mental health center in Indiana and the Eskenazi Health Center Primary Care.
PRINCIPAL INVESTIGATORS:
Todd Skaar, Ph.D. - Professor of Medicine, Indiana University School of Medicine, Division of Clinical Pharmacology
Paul Dexter, M.D. – Associate Professor of Clinical Medicine, Indiana University School of Medicine, Division of General Internal Medicine
Mount Sinai
Mount Sinai is an integrated health system committed to providing distinguished care, conducting transformative research and advancing biomedical education. Structured around seven member hospital campuses and a single medical school, the Health System has an extensive ambulatory network and a range of inpatient and outpatient services, from community-based facilities to tertiary and quaternary care.
The Health System’s seven member hospital campuses include Mount Sinai Beth Israel, Mount Sinai Queens, Mount Sinai West, Mount Sinai St. Luke’s, Mount Sinai Brooklyn, New York Eye and Ear Infirmary of Mount Sinai, and The Mount Sinai Hospital.
The Institute for Family Health (IFH) is a federally-qualified community health center (FQHC) network committed to high-quality, affordable health care for all. IFH strives for excellence at each of their 30 practices, most of which are located in NYC, while accepting all patients regardless of their ability to pay. They offer primary care, mental health, dental care, social work and many other services to patients of all ages and train health students and professionals at all levels.
PRINCIPAL INVESTIGATOR:
Carol Horowitz, M.D., M.P.H. - Professor, Icahn School of Medicine at Mount Sinai, Department of Population Health Science and Policy, Department of Medicine, Center for Community-Academic Research Partnerships
Duke University
Duke Medicine, which includes the Duke University Health System, the Duke University School of Medicine and the Duke University School of Nursing, combines research, clinical care and education at many different sites throughout the region and beyond. Duke University School of Medicine is among the most research-intensive of the U.S. medical schools, and the size, quality and scope of our research enterprise contributes substantially to the reputation of the School of Medicine, Duke University and the Duke University Health System. The entire medical campus encompasses 98 clinical, research and education buildings and employs more than 2,200 academic and clinical faculty physicians and researchers. Twenty-eight buildings on campus are dedicated to School of Medicine research and education.
The Duke Center for Applied Genomics and Precision was created to focus on developing these strategies and capabilities to enhance our ability to diagnose and predict patient outcomes across the continuum from health to disease. The Center aspires to be an intellectual home for genome-inspired biomarker discovery and development and the analytic and translational approaches to diagnostics and insights into disease biology. It is also a home for the rapidly evolving field of precision medicine - an evidence-based approach to the care of people and patients that uses innovative tools and data science to customize disease prevention, detection and treatment and improve the effectiveness and quality of care. The Center is highly interdisciplinary with ties to the health system and to university-wide faculty and students. As a hub and catalyst, the Center maintains strong, clear connections to other translational units at Duke, for example the Clinical and Translational Science Award programs, to help investigators unleash their full translational potential to advance this important area of science.
PRINCIPAL INVESTIGATORS:
Lori Orlando, M.D., M.H.S. - Associate Professor of Medicine; Director of the Precision Medicine Program in the Center for Applied Genomics and Precision Medicine
University of Florida (UF)
University of Florida Health is a medical network associated with the University of Florida. UF Health serves 1.5 million patients and is the largest comprehensive academic health center in the Southeastern US. OneFlorida Clinical Research Consortium is an enduring infrastructure to conduct patient-centered PCTs across Florida. Combined, the network includes health systems that provide care for approximately 15 million or 75 percent of all Floridians through 4,100 physician providers, 1,240 clinic/practice settings with a catchment area covePring all 67 Florida counties. The Nemours Foundation supports one of the largest integrated pediatric health systems in the U.S., including 50 pediatric subspecialty clinics, 16 partner hospitals, and primary care clinics throughout Delaware, Pennsylvania, and Florida.
PRINCIPAL INVESTIGATORS:
Julie Johnson, PharmD. -Dean and Distinguished Professor, College of Pharmacy, University of Florida
Vanderbilt Clinical Group
Vanderbilt University Medical Center (VUMC) is a comprehensive healthcare facility dedicated to patient care, research, and the education of healthcare professionals. For decades, VUMC has been at the forefront of pharmacogenomic discovery and its translation into clinical practice. In 2010, VUMC launched PREDICT (the Pharmacogenomic Resource for Enhanced Decisions in Care & Treatment) to empower providers and patients with the genetic information and electronic medical record tools to facilitate genetically-informed clinical decision-making at the point of care. Additionally, VUMC led the implementation of pharmacogenomic testing in several community and academic settings including Meharry Medical Center, Aurora Health System, and Sanford Medical Center during IGNITE I.
PRINCIPAL INVESTIGATORS:
Josh F. Peterson, M.D., M.P.H. – Associate Professor of Biomedical Informatics and Medicine
Josh C. Denny, M.D., M.S. - Professor of Biomedical Informatics and Medicine; Director of Center for Precision Medicine